MedTrace Logo

NT-NOA - Novel Treatment of Some Men With Non-Obstructive Azoospermia

NCT06706414 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2026-04-17

No results posted yet for this study

Summary

This clinical interventional study aims to assess whether treatment with denosumab in combination with letrozole can improve sperm production in infertile men with non-obstructive azoospermia selected by serum anti-mullerian hormone (AMH) as a positive predictive biomarker.

Conditions

  • Infertility, Male

Interventions

DRUG

Denosumab (Prolia)

Subcutaneous injection with 60 mg Denosumab once

DRUG

Letrozole (Aromatase Inhibitors)

Letrozole oral tablet 2.5 mg once daily

Sponsors & Collaborators

  • Martin Blomberg Jensen

    lead OTHER

Principal Investigators

  • Christian F.S. Jensen, MD, PhD. · Department of Urology, Herlev and Gentofte Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-03-01
Primary Completion
2026-08-31
Completion
2026-08-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06706414 on ClinicalTrials.gov